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Summary In this study we determined the level of tumour necrosis factor alpha (TNF-a) in liver and tumour tissue samples obtained from
patients with colorectal metastases confined to the liver, who were treated with isolated liver perfusion with TNF-a and melphalan. We
adapted a standard enzyme-linked immunosorbent assay kit for the quantification of TNF-a in serum to measure the amount of this cytokine
in solid tissue. For this purpose, we developed a buffer that lysed the tissues without affecting the TNF-a present. The minimum detection
level was about 2 pg of TNF-a per mg tissue. Using this technique, we found a significant increase in the TNF-a level after perfusion in the
liver tissue of all evaluable patients, which may explain the transient liver toxicity we observed in all patients. In tumour tissue, a significant
TNF-a increase was observed in one out of five patients. The level of TNF-a in all liver tissue samples and some of the tumours after
treatment by isolated liver perfusion was much higher than the peak serum concentrations obtained after systemic administration of the
maximum tolerated dose of TNF-a. Furthermore, we demonstrated that the level of TNF-a in the liver tissue samples was about seven to
eight times higher than in tumour tissue. We concluded that regional liver treatment resulted in a relatively high local level of TNF-a, but also
that this cytokine did not preferentially accumulate in tumour tissue.
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Tumour necrosis factor alpha (TNF-a) is a cytokine with a molec-
ular weight of 17 kDa, mainly produced by macrophages (Jaattela,
1991). It has many biological effects: it is known as an inflamma-
tory mediator; it plays a role in the rejection of transplanted
organs; and it has cytostatic and cytolytic effects on cancer cells
(Jaattela, 1991). The possibility to produce TNF-a by recombinant
DNA technology has enabled the exploration of the therapeutic
potential ofTNF-a as an anti-cancer agent, first in animal models
and later in human clinical trials (Alexander and Rosenberg, 1991;
Spriggs, 1991). TNF-a mediates its activity by binding to specific
receptors present on the surface of nearly all cell types. Two
distinct receptors with molecular weights of 55 kDa and 75 kDa
have been identified (Heller and Kronke, 1994). The cellular cyto-
toxic effect ofTNF-a may be the result ofthe formation ofoxygen
radicals in the cells exposed to TNF-a (Zimmerman et al, 1989).
The anti-tumour effect ofTNF-x in vivo has been hypothesized to
be mediated by selective damage to tumour-associated vasculature
(Jaattela, 1991).
Systemic administration of TNF-a has been applied in cancer
patients but appeared to be associated with severe toxicity.
Humans tolerate a maximum of 8-10 gg kg-' body weight of
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systemically administered TNF-a before life-threatening toxicities
set in, while tumour regression in mice required a dose ofapprox-
imately 400 ,ug kg-' (Blick et al, 1987; McIntosh et al, 1988;
Hieber and Heim, 1994). The maximum-tolerated dose of TNF-x
depends on the route of administration. A higher dose of TNF-a
can be used without toxic side-effects when administered via
isolated regional perfusion. In isolated limb perfusion a dose of
4 mg ofTNF-a may be administered safely to patients, as demon-
strated in a recent phase II study (Lienard et al, 1992). Isolated
perfusion may also be used for the liver in cases of primary or
secondary malignancies restricted to the liver. Therefore, we
recently treated colorectal cancer patients with metastases
confined to the liver by isolated liver perfusion with TNF-ca and
melphalan in a phase I clinical trial.
TNF-a can be determined in serum (Prince et al, 1987), but no
method is available to determine the level ofTNF-x in solid tissue.
It is important to know the amount ofTNF-a in the tissues because
the effect of TNF-a on the tumour may be related to the amount
bound to these tissues. There may also be a correlation between
hepatotoxicity and the amount ofTNF-a in liver tissue.
In this study we adapted a standard enzyme-linked immuno-
sorbent assay (ELISA) for the detection of serum levels ofTNF-x
to determine this cytokine in solid tissues. Next, we determined
the amount of TNF-a in biopsies of liver and tumour of six
patients with colorectal liver metastases treated by isolated liver
perfusion with TNF-x and melphalan. The TNF-a that we
measured was present either because of instilled TNF-a or
because ofcellular production caused by the treatment.
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Figure 1 The influence of the tissue lysis buffer on the detection of TNF-a by
a standard ELISA kit. Known concentrations of TNF-a were added to the
standard dilution buffer of the kit (0) or to the tissue lysis buffer (+). The
ELISA was performed as described in the Materials and methods. The
concentration of TNF-a (x-axis) is plotted vs the obtained colour signal as
measured at 450 nm (y-axis)
MATERIALS AND METHODS
Liver and tumour biopsies
Biopsies of liver and tumour tissue of six patients were taken just
before and directly after an isolated liver perfusion for 1 h with
either 0.4 (n = 5) or 0.8 (n = 1) mg of human recombinant TNF-a
(Boehringer-Ingelheim, Ingelheim am Rhein, Germany) together
with melphalan (L-PAM, 1 mg kg-' body weight; Wellcome,
Beckenham, Kent, UK). The samples were immediately frozen in
liquid nitrogen. None ofthe patients had other known liver aberra-
tions in their past history. During the isolated liver perfusion, the
liver was drained for 1 h with TNF-a and melphalan. The inflow
from the isolated circuit ran via the common hepatic artery and the
portal vein. The hepatic venous outflow returned the perfusate to
the oxygenator. The intestinal, renal and lower extremity blood
was shunted around the liver and brought back to the heart via the
axillary vein (Vahrmeijer et al, 1995).
Biopsies of normal liver tissue and liver metastases obtained
from colon cancer patients treated by partial liver resection were
used to develop the adaptions for the ELISA enabling the detec-
tion ofthe TNF-a levels in these solid tissues.
Detection of TNF-a in liver and tumour tissue
About 50 mg of tissue of each frozen sample was, after it was
weighed, solubilized with 450 ,l of lysis buffer [pH 7.4,
containing: 20 mM Tris-HCl; 150 mm sodium chloride; 2 mM
EDTA; 0.2% (w/v) sodium deoxycholate (Merck, Darmstadt,
Germany); 0.5% (v/v) Serdox NNP1O (Servo Delden, Delden, The
Netherlands); and 0.1% (w/v) aprotinin (Sigma, St Louis, MO,
USA)] by pounding this mixture with a pestle in a mortar. Cell
debris was removed by centrifugation of the solution for 15 min
(15 000 x g at 4°C). A standard 96-well plate ELISA kit for the
detection of TNF-ax in serum was used (CLB, Amsterdam, The
Netherlands), according to the protocol described by the manufac-
turer. TNF-a standards (Boehringer-Ingelheim, 0-100 ng ml-1)
were also included in each assay. Absorbance at 450 nm of each
well was measured by a 96-well plate reader (Titertek Multiskan
Plus MKII, Eflab, Finland).
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Figure 2 The influence of liver and tumour tissue on the detection of TNF-a
by a standard ELISA kit. Known concentrations of TNF-a were added to a
liver (+) and tumour (*) tissue sample. The ELISA was performed as
described in the Materials and methods. As a control, different
concentrations of TNF-a diluted in the lysis buffer only (0) were measured.
The concentration of TNF-a (x-axis) is plotted vs the obtained colour signal
as measured at 450 nm (y-axis). The background level of endogenous TNF-
a in the tissue was subtracted from the total level as measured in the ELISA
RESULTS
Method of quantification of TNF-a in liver and tumour
tissue
A standard ELISA kit for the detection of TNF-a in serum was
used for the determination ofTNF-ax in liver and tumour biopsies.
Because these biopsies had to be solubilized before they could be
used in the ELISA, the influence of the lysis buffer used for this
purpose on the detection level ofTNF-a was tested. This was done
by the addition of known concentrations of TNF-a to the lysis
buffer and subsequent measurement of the TNF-a level in this
solution by the ELISA to determine the recovery. The results
plotted in Figure 1 show that the lysis buffer we used had no influ-
ence on the detection level ofTNF-a as the curves with or without
lysis buffer did not significantly differ. Furthermore, the results
show that the minimum concentration that can be detected using
this method is about 0.1 ng ofTNF-a per ml.
A second important point may be the presence of proteolytic
enzymes in the liver as these may affect the detection ofTNF-a in
this tissue. To test this hypothesis, known concentrations of TNF-
a were added to liver and tumour tissue obtained from a patient
treated by partial liver resection and subsequently measured in the
ELISA. In Figure 2, the results of this experiment are shown. The
curves for the level of TNF-a, which was added to the samples,
did not significantly differ in the presence or absence of liver or
tumour tissue. Therefore, it can be concluded from these data that
the presence ofthese tissues had no influence on the quantification
of TNF-a using our method. A rather high background of TNF-a
was found in the tissues. Therefore, the level ofendogenous TNF-
a in liver and tumour tissue was determined in five samples of
each tissue obtained from biopsies of colorectal cancer patients
treated by partial liver resection. The endogenous level was found
to be 6.4 ± 1.3 pg ofTNF-a per mg of (frozen) liver tissue. In the
tumours, 2.1 ± 1.3 pg of TNF-a per mg of (frozen) tissue was
measured. The background level of endogenous TNF-a was
subtracted from the concentrations of TNF-a measured in liver
and tumour tissue, as shown in Figure 2.
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Table 1 Relevant data of the patients, including the results from the determinations of the amount of TNF-a in liver and tumour tissue before and after perfusion
Patient Sex Age Prior Dose of Dose of Liver tissue Tumour tissue
no. (years) therapya TNF-a (mg) melphalan (mg)b (pg of TNF-a per mg oftissue) (pg of TNF-a per mg of tissue)
before perfusion after perfusion before perfusion after perfusion
1 M 61 CH, S 0.4 84.0 5.0±0.8 31.0±8.7 < 1.5d <3.0
2 F 50 S 0.4 73.0 4.0±0.1 24.4±0.6 < 1.5 < 1.5
3 M 60 CH, S 0.4 83.0 NDC 23.2 ± 3.6 < 1.5 4.0± 0.1
4 M 65 S 0.4 84.5 14.5±2.5 25.8±3.4 2.8±0.3 3.0±0.7
5 M 51 S 0.4 90.0 7.8 2.7 30.2 ± 5.9 2.4± 0.1 < 1.6
6 M 63 S 0.8 69.0 4.0 0.2 ND 1.7± 0.1 ND
aCH, chemotherapy; S, surgery. bDose of melphalan also added to the isolated circuit (1 mg kg-' body weight). CND, not determined. din patients for whom the
amount of TNF-a was below detection level, the maximum amount of TNF-a that may be present was calculated from the weight of the tumour sample and the
lower limit of the standard curve.
Detection of TNF-ax in liver and tumour biopsies, taken
before and after isolated liver perfusion
Biopsies of liver and tumour were taken from six patients treated
by a 1 h isolated liver perfusion with TNF-a and melphalan.
Relevant data ofthe patients are listed in Table 1. All patients expe-
rienced hepatotoxicity as demonstrated by increased serum liver
enzymes the day after the perfusion (data not shown). In general,
these levels returned to normal values within the first week after
the treatment. The TNF-a concentration in the perfusate at the
beginning of the perfusion was 800 ng ml-1 and this concentration
decreased to approximately 400 ng ml-1 after the 1-h perfusion.
The amount of TNF-ax in the tissue, obtained before and after the
perfusion, was measured in triple determinations using the ELISA.
The mean sample size used in the ELISA was 62 ± 43 mg for the
liver samples and 63 ± 45 mg for the tumour samples. For one
patient no tissue was available after perfusion. The detected
amounts of TNF-a in liver and tumour tissue of each individual
patient are listed in Table 1. The TNF-a that we measured was
present either because of instilled TNF-a or because of cellular
production caused by the treatment. After perfusion, the level of
TNF-a in the liver was significantly (P < 0.05) increased in all
cases. Assuming that a human liver has a weight of 1700 g, it can
be calculated from our data that the amount of TNF-a in the liver
tissue after a 1-h isolated liver perfusion with 0.4 mg of TNF-at
ranges from 0.02 to 0.06 mg. This is 5-15% of the total dose
administered to the perfusate of TNF-a remaining in the liver
tissue. The TNF-a levels in the tumour samples were consistently
much lower than in the liver tissue samples. In 5 out of 11 tumour
samples tested, the level of TNF-a could be established. Six
tumour samples appeared to be too small or contained too little
TNF-a to reach the detection level of the ELISA. In one patient
(Table 1, no. 3), a significant (P < 0.05) increase of TNF-a in
tumour tissue, associated with the perfusion, was measured.
DISCUSSION
The apparent selective toxicity of TNF-ax for tumour cells as
opposed to normal cells has been the foremost reason for using
TNF-a in clinical trials. Although the widespread biological
activity of TNF-a in vivo complicates its use as a therapeutic
agent, its strong anti-tumour effects justify further investigations.
In particular, locoregional treatment with TNF-a appears to be
promising (Hieber and Heim, 1994) and is currently under investi-
gation (Lejeune et al, 1994; Klaase et al, 1995).
In this study we describe an assay to determine the level of
TNF-a in liver and tumour tissue samples. This assay enables the
measurement of TNF-a levels in many types of tissues, and its
application may therefore result in a better understanding of the
effectiveness of TNF-a in therapeutical protocols. The assay that
we used was an adapted standard ELISA for the detection ofTNF-
a in serum. An ELISA is attractive for use in TNF-a quantifica-
tion because it may be less prone to interference by external
factors, like other cytokines, which may influence growth of cells
as measured in quantitative bioassays. We have shown here that
neither the lysis buffer for the solid tissues we used nor compo-
nents in the tissues themselves affected the quantification ofTNF-
a. We conclude that, under the designated conditions, TNF-a is
not affected by proteolytic enzymes that are normally present in
the liver. The endogenous level of TNF-a in tumour and liver
tissue was similar in five different samples of each. Liver tissue
contained about three times more TNF-a than tumour tissue.
Kupffer cells, present in the normal liver and presumably present
in lowernumbers in the tumourtissue, mightbe responsible forthe
production ofthis TNF-a.
Determination of TNF-a in biopsies of liver and tumour tissue
of patients treated by isolated liver perfusion with TNF-a and
melphalan showed a significant increase of TNF-a in liver tissue
after perfusion in all the patients we tested. An important question
is whether the level of TNF-a obtained after isolated liver perfu-
sion is higher than in patients for whom it was administered in a
different way. After intravenous infusion of TNF-a at doses
> 100 g m-2, peak serum levels exceeding 1Ong mlr were
observed after 30 min (Feinberg et al, 1988). Intramuscular admin-
istration ofa dose ofTNF-a of 150 ig m-2 showed a peak level of
TNF-a in the serum of0.4 ng ml-' after 2 h (Blick et al, 1987). In
our study, after perfusion, approximately 3 ng of TNF-a per g of
tumour tissue and 20 ng ofTNF-a per g ofliver tissue was found,
demonstrating that the maximum level of TNF-a in liver tissue
after treatment by isolated liver perfusion is much higher than the
serum concentrations obtained after systemic treatment. The rela-
tive high level of hepatic TNF-a may account for the transient
hepatotoxicity that we observed in the patients treated. Approxi-
mately 3-4 ng of TNF-a per g of tumour tissue was found after
perfusion in biopsies of two out of five patients tested. In vitro
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tests have shown that tumour cell lines are killed starting at
concentrations in the range offg ofTNF-a per ml (Adamson and
Billings, 1992). Therefore, the TNF-a concentrations obtained in
the tumour after perfusion could well be sufficient to exert direct
toxic effects on the tumour cells. The TNF-a that we measured in
the tissue samples may be the TNF-a that was administered to the
isolated circuit but may also have been locally produced, e.g. by
Kupffer cells, as a result of secondary cytokine induction initiated
by the treatment (Renard et al, 1994). It may be possible that
the amount ofTNF-a found in the tumour samples correlated with
the presence ofcertain tumour-infiltrating cells, e.g. macrophages,
but, because of the small size of the samples, we were not able
to test this.
An explanation ofwhy TNF-a preferentially accumulates in the
liver instead of the tumour could be that TNF-a binds to the
vascular endothelial and that liver contains more blood vessels
than the metastases do. TNF-a is generally supposed to mediate its
anti-tumour activity in vivo as follows: binding of TNF-a to
endothelial cells results in an increase of expression of several
adhesion molecules (Renard et al, 1994). This increase stimulates
infiltration ofpolymorphonuclear cells (Cid et al, 1994), leading to
coagulative necrosis and/or haemorrhagic necrosis. Renard and
co-workers (1994) have found that TNF-a activates tumour-asso-
ciated as well as normal endothelial cells, resulting in an increase
ofadhesion molecules, however infiltration ofpolymorphonuclear
cells in combination with coagulative necrosis was seen exclu-
sively in the tumour. Ifthis is the anti-tumour mechanism ofTNF-
a then its activity is not only related to the amount ofTNF-a per
unit oftumour weight but also to the amount ofvascular endothe-
lium per unit oftumour weight. Thus, richly vascularized tumours
would be more susceptible to TNF-a than the relatively poorly
vascularized colorectal metastases in the liver. Therefore, vascu-
larization of the tumour probably has to be considered also in
order to relate anti-tumour effects and TNF-a levels.
In this study we described the development and application of
an assay that detects TNF-a in solid tissue. Using this method,
more precise correlations between in vivo and in vitro findings
obtained in studies with TNF-a may be made. This is of great
importance for the development of future strategies of successful
therapeutical treatments using TNF-a.
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